| abstract |
The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the Secemin-1 protein (= SCRN1) as a universal marker of different cancer types. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring SCRN1 in said sample. Measurement of SCRN1 can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery. |